Open PAR-25-248 CFDA 93.393 Discretionary

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)

Posted by National Institutes of Health

Opportunity snapshot. This Grants.gov announcement — Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) — is cataloged under number PAR-25-248 and tied to CFDA assistance listing 93.393, posted by National Institutes of Health. Grants.gov currently shows the opportunity as open, first posted on November 21, 2024. The funding category is Discretionary, delivered as a cooperative agreement.

Award economics. The award range on file is Varies by applicant. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.

Deadline and action path. Applications close on October 8, 2027 — roughly 490 days from today. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully — federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed — it helps clarify scope and scoring priorities.

Award Range

Varies by applicant

Close Date

October 8, 2027

Posted

November 21, 2024

Instrument

Cooperative Agreement

Description

This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.

Eligibility

00;01;02;04;05;06;07;08;11;12;13;20;22;23;25

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Parent Grant Program

CFDA 93.393

Cancer Research Grants

National Institutes of Health

View program →

Agency Contact

NIH Grants Information<br/>grantsinfo@nih.gov

Key Dates

Posted November 21, 2024
Close Date October 8, 2027
Archive Date November 13, 2027
Last Updated November 21, 2024

Frequently Asked Questions

What is this grant opportunity?
This is a federal funding opportunity titled "Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)", offered by National Institutes of Health. It is associated with CFDA program 93.393. This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of th...
Is this opportunity still open?
Yes, this opportunity is currently open for applications. The closing date is October 8, 2027.
How much funding is available?
The award range for this opportunity is Varies by applicant.
How do I apply?
Applications for federal grant opportunities are typically submitted through Grants.gov. Visit the official listing at grants.gov for application instructions, required documents, and submission deadlines.

More from National Institutes of Health

Open Closes November 2, 2028

Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)

View →
Open Closes November 2, 2028

Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)

View →
Open Closes November 2, 2028

Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)

View →
Open Closes January 25, 2028

Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)

View →
Open Closes March 5, 2029

Research Grants in Clinical Informatics (R01 Clinical Trial Optional)

View →

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Read our methodology — how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainGrants Editorial